Refsum Disease Treatment Market

Refsum Disease Treatment Market Outlook (2023 to 2033)

A study published by Fact.MR, says that the global refsum disease treatment market stands at US$ 1.48 billion in 2023. Worldwide demand for refsum disease treatment is predicted to accelerate at a CAGR of 5.6% and reach a market valuation of US$ 2.56 billion by the end of 2033.

Refsum disease is a rare genetic disease characterized by weakness or numbness of the hands and feet. The lack of peroxisomes enzyme that plays a significant role in the breakdown of phytanic acid is also due to Refsum disease. Mutation in the PHYH gene is one of the prominent causes of Refsum disease among people.

The disease commonly occurs in adulthood or late childhood. Certain fluctuations in the levels of phytanic acid can be noticed in the tissues of the brain, blood, and other organs that negatively affect an individual’s health. Intake of phytanic acid and diet management can be incorporated as significant solutions against Refsum disease. The prevalence of Refsum disease among men and women at equal rates is predicted to positively impact the demand for efficient treatment options.

• Germany and the United Kingdom in Europe and China and India in Asia pacific are key markets for Refsum disease treatment.

Increased funding from governments and respective governing bodies in healthcare facilities along with constant improvements in the regulatory and reimbursement policies are some pivotal factors driving the Refsum disease treatment landscape. Moreover, the rising awareness about this rare genetic disorder is estimated to fuel demand for genetic testing services.

Symptoms of Refsum disease appear late and sometimes can start at the age of 10 years. Some of these symptoms include cerebellar ataxia, night blindness, anosmia, deafness, ichthyosis, and weakness in arms and legs that appear very late. Therefore, complications associated with this disorder include cardiomyopathy and cardiac abnormalities, which can lead to premature death restraining market growth.

There are various challenges encountered by players in the Refsum disease treatment market such as poor healthcare systems and a lack of R&D activities, especially in middle- and low-income countries, which are projected to hinder market growth opportunities.

Fact.MR, a market research and competitive intelligence provider, in its newly published research report, mentions multiple aspects of Refsum disease treatment. Readers can get detailed insights about different aspects of the industry, including prominent growth drivers, limitations, new product launches, a country-level analysis, and numerous other aspects.

Report Attributes	Details
Refsum Disease Treatment Market Size (2023)	US$ 1.48 Billion
Anticipated Market Value (2033)	US$ 2.56 Billion
Global Market Growth Rate (2023 to 2033)	5.6% CAGR
Key Markets from Europe	Germany and the United Kingdom
Key Markets from Asia Pacific	India and China
Key End User of Refsum Disease Treatment Solutions	Hospitals
Key Companies Profiled	Ceuta Healthcare Limited Ikkumina, Inc. Fresenius Kabi Cook B. Braun Medical Inc. Medline Industries Inc. Cochlear Ltd. Igenomix Agilent Technologies BioRad Laboratories Inc.

Which Factors are Stimulating Refsum Disease Treatment Market Growth?

“Increasing Awareness about Genetic and Rare Disorders”

In recent years, awareness related to genetic and rare disorders has been increasing among various people leading to significant investments in treatment and medications. Rising genetic mutations that are led by various environmental factors increase the chances of Refsum disease occurrence, which fuels demand for more efficient genetic therapies, driving opportunities for market players.

“Investments in R&D Activities for Innovation and Development in Healthcare Sector”

Increased investments in R&D activities for the development & innovation of new medications, treatment procedures, and medical devices is projected to foster opportunities for providers of Refsum disease treatment solutions. Governments from different countries around the world are investing to improve healthcare infrastructure in their respective areas. In addition, rising funding & reimbursement policies along with improving regulatory frameworks are also projected to open up lucrative opportunities for prominent as well as new entrants in the landscape over the coming decade.

What are the Challenges Encountered by Refsum Disease Treatment Providers?

“Complications of Refsum Disease Leading to Premature Death”

There are certain complications that are associated with Refsum disease. Some of these complications include cardiomyopathy and cardiac abnormalities, which can sometimes lead to premature death. Thus, these factors are predicted to adversely impact demand for Refsum disease treatment solutions.

How are Start-ups Advancing in This Niche Market?

“Clinical Trials and Medical Research Opening New Horizon for Start-ups”

Start-ups are trying to enter into the Refsum disease landscape and invest at a significant rate to ensure more efficient treatment solutions for patients. They are predicted to come up with solutions that cause minimal side effects to patients and are trustworthy. Therefore, clinical trials and medical research are some appropriate methods adopted by start-ups to provide treatment advancements and thus secure their position in the market.

Country-wise Insights

Why is the United States Considered Highly a Lucrative Market for Refsum Disease Treatment Providers?

“Rising Awareness about Refsum Disease Among Americans”

The United States is projected to operate as a prominent market in the North American region over the next 10 years. The growth in this landscape is attributed to the rising awareness among the majority of Americans about Refsum disease. In addition, higher healthcare expenditure by people in this country is also anticipated to positively impact demand for efficient treatment options for different disorders, including Refsum disease treatment.

Which European Countries are Generating High Revenue for Market Players?

“Favourable Reimbursement Policies in United Kingdom and Germany”

The United Kingdom and Germany are prominent markets in Europe contributing to significant revenue streams in the European region. Increasing support from governments of these countries in R&D activities related to healthcare services is predicted to support the expansion of the Refsum disease treatment landscape. In addition, improved reimbursement policies in Germany and the United Kingdom are also contributing to the expansion of the healthcare facilities provided for Refsum disease.

Why are Providers of Refsum Disease Treatment Solutions Attracted to India and China?

“Rapidly Rising Investments in Healthcare Infrastructure”

India and China are two prominent markets from Asia Pacific that are generating a significant amount of profit for Refsum disease treatment providers. Increasing cases of Refsum disease in these countries are directly boosting demand for more efficient treatment solutions. Moreover, the active participation of government as well as non-government organizations to bring developments in the healthcare sector is also contributing to the expansion of the Refsum disease treatment landscape.

Category-wise Insights

Which Type of Treatment is Extensively Used for Refsum Disease?

“Increasing Intake of Medications for Refsum Disease Treatment”

Surgery and medication are two popular types of treatment available against Refsum disease. Medications are available in the market in different forms such as pills and capsules, which need oral consumption by patients on a routine basis. They help in slowing down or delaying the worsening of symptoms. The efficiency of these medications is dependent on an individual’s body condition as they need absorption into the human system through blood vessels.

Which End Use is a Key Contributor to Market Growth?

“Availability of More Advanced Healthcare Solutions in Hospitals”

Hospitals, research centers, clinics, and home care settings are some popular end users of Refsum disease treatment solutions across geographies. Currently, Refsum disease treatment is provided by various hospitals as an effective method to cure the condition. The availability of numerous qualified doctors as well as scientists that are skilled enough to offer proper care and diagnosis in hospitals are attracting patients instead of going to other care providers.

Key Market Players

Leading companies in the Refsum disease space are investing at a significant rate in R&D activities to bring innovations in treatment options and expand their footprints across geographies. Further, they are also adopting numerous strategies, including collaborations, product launches, etc., to remain competitive over the coming decade.

For instance :

• In April 2019, Progenity Inc. launched its test against monogenic diseases, the Resura Prenatal Test. This test kit is one of its types and is a non-invasive, customizable, and commercially available developed for single-gene disorders. This newly developed test kit broadens prenatal testing options for expectant parents to include a non-invasive and safe test, which is tailored to reduce the risk of some particular genetic diseases in the family.
• The same company also announced improvements in its existing Innatal Prenatal Screen, which is a popular non-invasive prenatal test designed especially against chromosomal aneuploidies. The test offers greater sensitivity and specificity to evaluate aneuploidy across multiple chromosomes tested in some recent validations.

Key Refsum disease treatment product manufacturers include Ceuta Healthcare Limited, Ikkumina, Inc., Fresenius Kabi, Cook, B. Braun Medical Inc., Medline Industries Inc., Cochlear Ltd., Igenomix, Agilent Technologies, and BioRad Laboratories Inc.

Segmentation of Refsum Disease Treatment Industry Research

• By Type :

  • Surgery
  • Medication

• By End User :

  • Hospitals
  • Clinics
  • Research Centers
  • Homecare

• By Age Group :

  • Pediatric
  • Adults

• By Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa